Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3088MR)

This product GTTS-WQ3088MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3088MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10418MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ3860MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ11931MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ15364MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ8247MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ9628MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ13061MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ270MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW